
    
      This is a prospective, single-center, single-arm, open label feasibility study aiming to
      enroll at least 10 patients and a maximum of 15 patients to achieve 30 treated sinuses. The
      objective of this feasibility study is to assess the performance, safety and initial signals
      of efficacy of the drug-eluting Propel Nova Sinus Implant when used in chronic sinusitis (CS)
      patients undergoing sinus surgery of peripheral sinus ostia.
    
  